Astria Therapeutics

Latest Pharma and Bio Collaborations

Cigna: Express Scripts enhances strategies to support access to care at independent pharmacies

May 23
Last Trade: 332.61 -5.22 -1.55

Based on guidance from its Independent Pharmacy Advisory Committee, Express Scripts will collaborate with CPESN ® USA through its IndependentRx initiative ST. LOUIS, May 23, 2024 /PRNewswire/ -- Express Scripts, the pharmacy benefits services business of The Cigna Group's (NYSE: CI) Evernorth, is making it easier for people to access a broader range of care services at independent pharmacies. This new collaboration with...Read more

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

May 23
Last Trade: 2.21 0.17 8.33

The Leidos team’s Next-Generation Medical Countermeasures (MCMs) Successfully Formulated with Company’s Proprietary Thin Film Freezing Technology MCM Candidates Demonstrated Chemical and Biological (CB) Neutralizing Activity in Well-Validated In Vitro and Ex Vivo Models FORT WORTH, Texas, May 23, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on...Read more

Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22
Last Trade: 26.62 -0.23 -0.86

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s...Read more

Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline

May 22
Last Trade: 48.30 -0.68 -1.39

SOUTH SAN FRANCISCO, Calif. and NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Royalty Pharma plc (Nasdaq: RPRX) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the company’s expanding cardiovascular pipeline while diversifying access to capital as the company advances its muscle biology-directed...Read more

Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Administration Protocol For Major Depressive Disorder

May 22
Last Trade: 0.44 0.05 11.39

VANCOUVER, British Columbia, May 22, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as botanical psilocybin and MDMA, has entered a Letter of Intent (LOI) with ATMA Journey Centers (ATMA). ATMA is a pioneering Canadian firm focused on advancing innovative solutions in...Read more

Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism

May 22
Last Trade: 106.06 2.12 2.04

DUBLIN, May 22, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced a strategic collaboration with Life Science Cares to drive social impact through employee volunteerism in the United States. This partnership reinforces Jazz's commitment to supporting the communities in which employees work and live. Life Science Cares is a collective effort to activate the financial and human capital of the life sciences...Read more

Bio-Techne Highlights Recently Announced Top-Line Biomarker Data From Partner, Regulus Therapeutics, Using The Company's Proprietary Technology

May 22
Last Trade: 80.79 0.38 0.47

MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus' positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429...Read more

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

May 22
Last Trade: 0.91 0.01 1.53

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies         LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered...Read more

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

May 21
Last Trade: 0.89 0.005 0.57

Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depression MIAMI, May 21, 2024 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, announced it is in advanced discussions with...Read more

Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 21
Last Trade: 14.19 0.61 4.49

Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the product HYDERABAD, India and REYKJAVIK, Iceland, May 21, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...Read more

HEALWELL AI’s Pentavere Partners with Sunnybrook and Successfully Demonstrates its AI Powered Clinician Co-pilot System Can Improve Cancer Staging in Prestigious Peer-Reviewed Medical Journal

May 21
Last Trade: 1.72 0.00 0.00

Pentavere partnered with Sunnybrook Health Sciences Centre to demonstrate how Pentavere’s DARWEN™ AI platform can help enhance cancer staging to improve patient outcomes. Results of this collaboration were presented at the prestigious American Head and Neck Society annual conference and published in JAMA Otolaryngology, which is the highest impact journal for Otolaryngologic or ‘head and neck’ cancers. This is the first published...Read more

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer

May 20
Last Trade: 1.78 -0.04 -2.20

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+)...Read more

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 20
Last Trade: 0.57 -0.02 -3.19

New Study to Confirm Overdose Protection Across Full Dosage Range of Breakthrough Therapy Opioid PF614-MPAR SAN DIEGO, CA / ACCESSWIRE / May 20, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced the renewal of its collaboration with...Read more

TFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical Testing

May 20
Last Trade: 2.21 0.17 8.33

FORT WORTH, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that, in collaboration with Cleveland Clinic, the Company is advancing multiple multivalent universal influenza...Read more

Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI

May 16
Last Trade: 1.69 0.06 3.68

DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company’s recently acquired continuous glucose monitor (CGM) biosensor technology. Under this...Read more

Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases

May 15
Last Trade: 1.87 -0.07 -3.61

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif., May 15, 2024 /PRNewswire/ --Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the...Read more

Telo Genomics and Emery Pharma Announce Collaboration

May 15
Last Trade: 0.18 -0.01 -5.26

Toronto, Ontario--(Newsfile Corp. - May 15, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications in oncology is pleased to announce that the Company has signed a collaboration agreement with Emery Pharma ("Emery"). Emery is a full-service contract research organization (CRO) offering...Read more

Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial

May 15
Last Trade: 1.09 0.03 2.83

Anticipated evaluation to include combination therapy featuring treatment regimen of checkpoint inhibition and chemotherapy utilized in cohort 1 of the GOBLET study GCAR is launching a new master protocol for pancreatic cancer with the intent to create a registration-enabling pathway for investigational therapies Innovative adaptive design could accelerate registrational study timeline and provide substantial cost savings compared to...Read more

Sojitz and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

May 14
Last Trade: 0.66 0.0046 0.70

Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a...Read more

Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics

May 14
Last Trade: 21.39 0.25 1.18

Collaboration aims to accelerate the development of personalized therapies and transform patient care through the use of precision medicine TAMPA, Fla. & LOS ANGELES / May 14, 2024 / Business Wire / Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer...Read more

GE HealthCare and Medis Medical Imaging Announce Collaboration Focused on Non-Invasive Coronary Assessments to Help Advance Precision Care in Treatment of Coronary Artery Disease

May 14
Last Trade: 79.85 0.52 0.66

Collaboration seeks to advance precision care by providing an alternative, non-invasive approach to the assessment of coronary physiology. Both companies will focus on the integration of Medis QFR into GE HealthCare’s cath lab environment built around the Allia Platform to enable a seamless user experience. CHICAGO / May 14, 2024 / Business Wire / Today, GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical...Read more

Senseonics and Mercy Collaborate to Improve Diabetes Population Health Management

May 13
Last Trade: 0.44 -0.0051 -1.14

Enhancing patient care and advancing innovation with the only long-term implantable continuous glucose monitor GERMANTOWN, Md. & CHESTERFIELD, Mo. / May 13, 2024 / Business Wire / Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitor (CGM) systems for people with diabetes, in partnership with our global...Read more

AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

May 13
Last Trade: 157.06 -1.20 -0.76

Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH CHICAGO, Ill. and NEW YORK, May 13, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals today announced a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders. This...Read more

TriLink BioTechnologies collaborates with Johns Hopkins University to establish a new RNA Innovation Center

May 13
Last Trade: 10.85 0.07 0.65

The collaborative center will help to lower barriers to RNA innovation and discovery SAN DIEGO / May 13, 2024 / Business Wire / TriLink BioTechnologies (TriLink®), a Maravai™ LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, is collaborating with the Johns Hopkins University to accelerate transformational research in RNA therapeutics and discovery. A new center within the Johns Hopkins...Read more

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

May 13
Last Trade: 7.21 -0.21 -2.83

Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights  Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50  Conference call and webcast scheduled for 8:00 a.m. ET...Read more

Intensity Therapeutics and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

May 10
Last Trade: 5.05 -0.02 -0.39

SHELTON, Conn., May 10, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company executed a collaboration agreement with The Swiss Group for...Read more

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

May 9
Last Trade: 51.90 1.27 2.51

The companies share design of global Phase 3 trial, iMMagine-3; will evaluate anito-cel in patients exposed to both an immunomodulatory (lMiD) drug and an anti-CD38 monoclonal antibody Anito-cel will be manufactured from Kite’s Frederick, Maryland facility for iMMagine-3 as the successful technical transfer is complete Remain on track to present preliminary data from the iMMagine-1 trial by end of the year REDWOOD CITY, Calif. &...Read more

Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients

May 9
Last Trade: 1.97 0.03 1.29

MARLBOROUGH, Mass. and FRANKFURT, Germany, May 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and NeraCare, a leading developer of laboratory tests for the prognosis of melanoma patients, announced an exclusive agreement today under which the parties will develop market opportunities for combining Akoya’s PhenoImager HT platform and NeraCare’s Immunoprint assay for patient stratification...Read more

Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis

May 9
Last Trade: 262.78 1.38 0.53

The Danaher Beacon for Brain Injury Diagnostics seeks to identify mild Traumatic Brain Injury (TBI) earlier and more precisely. Scientists will evaluate new blood-based biomarkers using highly sensitive technology from Beckman Coulter Diagnostics. This approach could potentially be adapted for diagnosis of other neurological conditions. WASHINGTON, May 9, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and...Read more

Coherus BioSciences Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

May 8
Last Trade: 1.91 -0.10 -4.98

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus; Nasdaq: CHRS) today announced that the Cancer Research Institute (CRI) and its Immunotherapy Platform Study in Platinum-Resistant High-Grade Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have selected LOQTORZI (toripalimab-tpzi), anti-PD-1 antibody, to explore in combination with ENB-003, a first-in-class small molecule inhibitor of...Read more

Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines

May 8
Last Trade: 2.42 -0.25 -9.21

Company currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccines  SAN JOSE, Calif., May 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a joint development agreement with Cleveland Clinic to develop novel...Read more

Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research

May 8
Last Trade: 0.08 -0.005 -5.88

VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the expansion of two research collaborations to align with its recently announced collaboration with the Deep Docking AI Drug Discovery Platform. On March...Read more

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 7
Last Trade: 1.75 -0.08 -4.37

CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform  Phase 1 first-in-human study expected to start in first half of 2024  Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma  SOUTH...Read more

QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

May 7
Last Trade: 43.73 0.56 1.30

Venlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a cooperative research and development agreement (CRADA) with the U.S. Federal Bureau of Investigation (FBI) to develop a novel test for its QIAcuity digital PCR devices that will boost forensics by improving the quantification of DNA in human samples. The collaboration aims to develop a...Read more

Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia

May 7
Last Trade: 2.22 0.04 1.83

SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a partnership with Avance Clinical, a leading Contract Research Organization (CRO), to conduct a Phase II clinical trial in Australia. This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury (TBI),...Read more

BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million

May 7
Last Trade: 45.12 -0.03 -0.07

Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosis GSK to participate in Series C Extension with equity investment Series C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of...Read more

Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications

May 6
Last Trade: 0.62 -0.02 -2.65

Gossamer to receive $160 million development reimbursement payment and eligible to receive up to $146 million in regulatory and $180 million in sales milestones - Gossamer leading US commercialization activities in PAH and PH-ILD50 / 50 commercial profit split in US and global development cost sharing arrangement  Chiesi, a global leader in the pulmonary and rare disease spaces, obtains exclusive ex-US commercial rights, with...Read more

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

May 6
Last Trade: 6.23 0.00 0.00

XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development. The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology indications,...Read more

Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry

May 3
Last Trade: 262.78 1.38 0.53

WOBURN, Mass., May 3, 2024 /PRNewswire/ -- Curiox Biosystems Co. Ltd (Curiox), a leader in the innovation of life science research technologies, and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, announce a strategic partnership to provide researchers with a one-stop solution for hands-free washed sample preparation for flow cytometry. The agreement combines the Laminar...Read more

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

May 2
Last Trade: 0.46 0.01 2.44

New research collaboration will explore the differentiation of eblasakimab's mechanism of action versus biologic therapies for atopic dermatitis (AD), dupilumab and lebrikizumab. The findings will deepen understanding of the biology underlying the recent finding that some AD patients may respond to eblasakimab even after having an inadequate response to dupilumab. The first part of the collaboration will focus on receptor biology and...Read more

LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-1 Patient Care with Real-time, At-Home Monitoring of Blood Pressure and Body Composition

May 2
Last Trade: 7.84 0.22 2.89

NEW YORK and BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc.® (Nasdaq: LFMD), a leading provider of virtual primary care services, and Withings Health Solutions, a leader in digital health technology, announce a new strategic partnership designed to revolutionize weight management patient care by providing LifeMD’s GLP-1 weight-loss patients with Withings advanced in-home health monitoring devices, including the Body Pro 2...Read more

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

May 2
Last Trade: 7.48 0.02 0.27

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US’s leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement to inform the development of a scalable and...Read more

AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies

May 1
Last Trade: 3.85 0.00 0.00

VANCOUVER, British Columbia / May 01, 2024 / Business Wire / AbCellera (Nasdaq: ABCL), Viking Global Investors (“Viking”), and ArrowMark Partners (“ArrowMark”) announced today that they have entered into a collaboration to advance new antibody drug programs with an aim to launch multiple asset-based companies. The first two programs will be in the area of immunology. The collaboration brings together Viking and ArrowMark’s expertise in...Read more

Astellas Pharma and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology

May 1
Last Trade: 2.97 0.02 0.68

Leverages Poseida's proprietary allogeneic CAR-T platform to develop innovative convertibleCAR® programs targeting solid tumors  TOKYO and SAN DIEGO, May 1, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, "Poseida") today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary...Read more

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

May 1
Last Trade: 5.63 -0.20 -3.43

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The extension also has options to extend the...Read more

Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements with PathAI

May 1
Last Trade: 141.28 1.24 0.89

Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce costs SECAUCUS, N.J. and BOSTON, May 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today...Read more

WELL Health Technologies Announces Collaboration with Microsoft to Accelerate Healthcare's Digital Transformation

April 30
Last Trade: 3.73 0.02 0.54

The collaboration aims to improve North American healthcare by integrating Microsoft Azure and its AI with WELL's digital health platform to improve clinical outcomes, optimize costs, and ensure top-tier data privacy and security. The integration is expected to streamline WELL's cloud and infrastructure environments and position it to improve its ability to scale and offer leading edge solutions across all of its business units, with...Read more

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

April 30
Last Trade: 147.76 -1.62 -1.08

The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam's innovative RNAi technologies ZUG, Switzerland, April 30, 2024 /CNW/ -- Medison Pharma ("Medison"), a global...Read more

Bayer and Evotec Collaborate to Advance Precision Cardiology

April 30
Last Trade: 4.77 -0.16 -3.25


Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement

April 29
Last Trade: 0.63 -0.02 -2.64

Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect™ Colon Disease Screening Test EZ Detect™ is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwide Aware® is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women...Read more

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

April 29
Last Trade: 7.48 0.02 0.27

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to...Read more

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases

April 29
Last Trade: 41.24 -0.30 -0.72

Collaboration combines Repertoire's industry leading DECODE™ platform that uniquely maps the immune synapse to develop T cell targeted immune medicines with Bristol Myers Squibb's world-leading expertise in developing and commercializing innovative immune medicines Repertoire will receive an upfront payment of $65 million and is eligible to receive up to $1.8 billion in milestone and other payments and tiered royalties CAMBRIDGE,...Read more

Owlet Forges Groundbreaking Partnership with Wheel to Launch Virtual TeleHealth Services Platform

April 25
Last Trade: 3.65 -0.05 -1.35

The partnership is set to transform infant care by providing virtual telehealth services to caregivers, increasing access to innovative medical-grade monitoring. LEHI, Utah / Apr 25, 2024 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, announces a strategic partnership with Wheel, an industry leader in providing virtual patient-centric care. Through this partnership, Wheel...Read more

FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids

April 25
Last Trade: 11.48 0.00 0.00

HOUSTON, April 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics") and Charles River Laboratories (“Charles River”), a highly respected, global provider of drug discovery, development, and manufacturing solutions, today announced the signing of a letter of intent allowing for the transfer, testing and validation of FibroBiologics’ technology. This agreement comes ahead of entering into an anticipated...Read more

Regeneron Pharmaceuticals and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

April 25
Last Trade: 985.02 4.45 0.45

Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a...Read more

Moderna and OpenAI Collaborate To Advance mRNA Medicine

April 24
Last Trade: 166.61 2.60 1.59

Generative AI will help advance Moderna's broad and diverse portfolio to maximize the Company's impact on patients Moderna embeds OpenAI's generative AI tools throughout its organization and sees early success with broad adoption of ChatGPT Enterprise CAMBRIDGE, MA AND SAN FRANCISCO, CA / ACCESSWIRE / April 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) and OpenAI today announced their ongoing collaboration to co-innovate with a shared...Read more

Cohere Health and Humana Expand Prior Authorization Partnership, Adding Diagnostic Imaging and Sleep Services

April 23
Last Trade: 349.30 -2.92 -0.83

New solutions elevate and expedite patient care with upstream moments of influence  BOSTON and LOUISVILLE, Ky., April 23, 2024 /PRNewswire/ -- Cohere Health, a recognized leader in clinical intelligence and prior authorization automation, announced that Humana Inc. (NYSE: HUM) will expand its use of Cohere's prior authorization platform for diagnostic imaging and sleep services. "Expanding our partnership...Read more

Mobile-health Network and Online Pharmacy, Lifepack, Sign Partnership Facilitating Cooperation in Singapore and Indonesia

April 23
Last Trade: 1.80 0.00 0.00

SINGAPORE, April 23, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or the “Company”), a pioneering Asia-Pacific (“APAC”) telehealth provider, has announced a strategic partnership with PT Indopasifik Teknologi Medika Indonesia, better known as Lifepack, an online prescription provider based in Indonesia. The collaboration aims to improve healthcare accessibility in Indonesia by bringing affordable and...Read more

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

April 23
Last Trade: 4.91 -0.25 -4.84

Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company...Read more

Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research

April 23
Last Trade: 0.44 0.05 11.39

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC). The project, entitled, “Genetic Identification of Psilocybin Containing Mushroom,” will...Read more

NeuroSense Therapeutics and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

April 22
Last Trade: 1.17 0.007 0.60

CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD...Read more

GE HealthCare’s MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

April 22
Last Trade: 79.85 0.52 0.66

Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta’s radiation therapy offerings with GE HealthCare’s MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta’s existing global commercial collaboration...Read more

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster

April 22
Last Trade: 41.24 -0.30 -0.72

Bristol Myers Squibb will utilize Cellares’ proprietary Cell Shuttle, a next-generation end-to-end, fully automated cell therapy manufacturing platform, for the clinical and commercial-scale manufacturing of select CAR T cell therapies Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart...Read more

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

April 22
Last Trade: 33.27 -0.07 -0.21

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disorders This promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets...Read more

Evotec And Variant Bio Enter Strategic Partnership To Discover And Develop Fibrosis Treatments

April 18
Last Trade: 4.77 -0.16 -3.25

Collaboration leverages variant bio's cutting-edge genomic discovery platform and evotec's integrated end-to-end R&D platform and disease area expertise to address unmet medical need in fibrotic indications Commercial terms include research funding and milestones and/or royalty payments to evotec based on the overall success of the program HAMBURG, Germany and SEATTLE, April 18, 2024 /PRNewswire/ -- Evotec SE...Read more

Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics

April 18
Last Trade: 1.19 -0.02 -1.65

REDWOOD CITY, CA / ACCESSWIRE / April 18, 2024 / Biotricity Inc. (NASDAQ:BTCY) a leading Technology-as-a-Service (TaaS) company at the forefront of medical diagnostics and consumer healthcare, announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics. Biotricity will work closely with healthcare professionals to optimize patient interaction protocols and streamline...Read more

IGM Biosciences Announces Refocusing of Sanofi Collaboration

April 17
Last Trade: 9.55 -0.49 -4.88

MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that the Company’s exclusive worldwide collaboration agreement with Sanofi to create and develop IgM agonist antibodies will now focus exclusively on immunology/inflammation targets. IGM will retain global rights to its proprietary...Read more

Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S.

April 17
Last Trade: 3.87 -0.12 -3.01

Agreement designed to provide patients and caregivers access to innovative home dialysis with the Tablo® Hemodialysis System SAN JOSE, Calif. / Apr 17, 2024 / Business Wire / Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, and U.S. Renal Care, the largest privately held kidney care provider in the United States, announced...Read more

Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides

April 16
Last Trade: 139.40 -1.11 -0.79

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development...Read more

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines

April 16
Last Trade: 3.69 -0.28 -7.05

Agreement creates strong synergies between CureVac's unique end-to-end mRNA capabilities and MD Anderson's translational and clinical research expertise Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need MD Anderson responsible for leading initial Phase 1/2 studies; CureVac retains worldwide exclusive rights to late-stage development,...Read more

Elevance Health and Clayton, Dubilier & Rice Sign Agreement to Launch Strategic Partnership to Advance Primary Care Delivery

April 15
Last Trade: 521.41 -22.53 -4.14

Collaboration will leverage the strengths of three care provider entities that will come together to deliver value to consumers and employers across the healthcare journey INDIANAPOLIS / Apr 15, 2024 / Business Wire / Elevance Health, Inc. (NYSE: ELV) and Clayton, Dubilier & Rice (CD&R) announced an agreement to form a strategic partnership to accelerate innovation in primary care delivery, enhance the healthcare experience,...Read more

Strategic Collaboration between Adaptimmune Therapeutics and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

April 12
Last Trade: 1.05 0.04 3.96

Company remains focused on launching afami-cel later this year with a PDUFA date of August 4th and developing its broader sarcoma franchise Update on afami-cel launch plans to be provided at the April 18th Investor Day Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - April 12, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy,...Read more

Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

April 10
Last Trade: 1.56 -0.05 -3.11

Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson & Johnson  NEW HAVEN, Conn. / Apr 10, 2024 / Business Wire / Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a collaboration with Johnson & Johnson1 to...Read more

Ginkgo Bioworks and Novo Nordisk Expand Alliance to Collaborate Across R&D Value Chain

April 10
Last Trade: 0.66 0.0046 0.70

BOSTON, April 10, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is developing the leading platform for cell programming and biosecurity, today announced the expansion of its strategic partnership with global healthcare leader Novo Nordisk under a framework agreement that initially is contemplated to run over five years.  Novo Nordisk and Ginkgo have created a flexible and scalable new model for their R&D partnership....Read more

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 

April 10
Last Trade: 40.85 0.89 2.23

MoonLake to tap into Komodo’s technology and real-world data to unlock the full potential of its next-gen Nanobody® therapy San Francisco, US and Zug, Switzerland, April 10, 2024 – MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX) a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a new technology partnership to help improve treatment for...Read more

Nano-X Imaging Announces Collaboration with AhealthZ and SCL Science to Enter South Korean Market

April 9
Last Trade: 8.43 -0.16 -1.86

AhealthZ to aid Nanox’s pursuit of local authorizations and licenses for Nanox.ARC in South Korea SCL Science to integrate Nanox’s artificial intelligence solutions in operations PETAH TIKVA, Israel, April 09, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced a new collaboration to advance the Nanox.ARC 3D imaging system and Nanox...Read more

NeuroSense Therapeutics Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics

April 9
Last Trade: 1.17 0.007 0.60

NeuroSense will leverage its extensive experience in biomarker utilization to advance early diagnosis and treatment in the neurodegeneration field Lonza to develop, optimize, and qualify a method utilizing Neuron-Derived Exosomes ("NDEs"), set to be integrated into the clinical development program of PrimeC by NeuroSense Lonza's Dev-on-Demand solution to enable NeuroSense to access Lonza's process development with rapid initiation,...Read more

Charles River Laboratories Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics

April 9
Last Trade: 217.21 -0.34 -0.16

HQ plasmid DNA production to support Phase I trials for gene therapy targeting Bardet-Biedl Syndrome WILMINGTON, Mass. / Apr 09, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality (HQ) gene of interest plasmid to support the...Read more

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

April 9
Last Trade: 1.58 -0.03 -1.86

Provides a holistic breast health solution, including breast cancer screening focused on quality, safety and efficiency, breast cancer detection, breast density assessment, and risk evaluation Expands access to iCAD’s AI-powered ProFound Breast Health Suite and Densitas’ AI solutions to patients and medical professionals worldwide NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a...Read more

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

April 9
Last Trade: 15.17 0.00 0.00

Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation Nurix anticipates nominating a clinical candidate within the first year of the extension SAN FRANCISCO, April 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients...Read more

Augmedix Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care

April 9
Last Trade: 1.14 0.02 1.79

SAN FRANCISCO and ORLANDO, Fla., April 09, 2024 (GLOBE NEWSWIRE) -- In a significant move to streamline healthcare workflows and allow clinicians to focus on patient care, Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, announced today that it has integrated with Andor Health, an AI-first cloud-based communication and collaboration platform for virtual care. The alliance aims to harness the power...Read more

IQVIA and Salesforce Expand Global Partnership to Accelerate the Development of Life Sciences Cloud

April 8
Last Trade: 229.60 2.51 1.11

RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO, CA / Apr 08, 2024 / Business Wire / IQVIA (NYSE:IQV), a leading global provider of data, analytics, technology and services to the life sciences industry, and Salesforce (NYSE:CRM), the #1 AI CRM, today announced an expanded global strategic partnership to accelerate the development of Salesforce’s Life Sciences Cloud, a next-generation customer engagement platform for the global life...Read more

Cardio Diagnostics Enters Into a Nationwide Telehealth Agreement with Navierre

April 4
Last Trade: 0.69 -0.01 -2.03

CHICAGO / Apr 04, 2024 / Business Wire / Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology platform which revolutionizes how patients access healthcare and serves as a true health companion for every stage from birth to the golden years with a robust care navigation, wellness, and chronic care...Read more

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

April 4
Last Trade: 77.25 0.55 0.72

Strategic partnership expands Biognosys’ services to include Alamar’s NULISA assays as well as joint scientific research in biofluid-based proteomics Complementary value of Biognosys’ DIA-MS unbiased proteomics platform and Alamar’s game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass...Read more

Charles River Laboratories to Perform Plasmid Production for Ship of Theseus

April 4
Last Trade: 217.21 -0.34 -0.16

GMP grade plasmid DNA to serve as a direct therapeutic targeting various indications WILMINGTON, Mass. / Apr 04, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus, a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manufacturing Practice- (GMP) plasmid DNA contract development and manufacturing organization (CDMO) agreement....Read more

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

April 4
Last Trade: 3.40 0.00 0.00

Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approved Sabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer’s disease (AD) Acumen is on track to initiate a Phase 2 clinical trial evaluating sabirnetug...Read more

Healthcare Triangle Announces Strategic Partnership with Cynomi to Enhance Cybersecurity in Healthcare

April 4
Last Trade: 0.70 -0.04 -5.97

PLEASANTON, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leading provider of healthcare IT solutions, is thrilled to announce its partnership with Cynomi, a pioneer vCISO platform vendor. This collaboration introduces an innovative Virtual Chief Information Security Officer (vCISO) service tailored specifically for the healthcare provider market,...Read more

The Oncology Institute and Healthly Forge Strategic Alliance to Elevate Cancer Care Access to Healthly Patients Across Southern California

April 4
Last Trade: 0.53 -0.03 -4.55

CERRITOS, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) and Healthly, a rapidly growing healthcare company with over 180 primary care physicians, support services, and a focus on preventive medicine, have announced a strategic collaboration aimed at extending high-quality cancer care services to patients throughout Southern California. Commencing July 1, 2024, TOI will offer its...Read more

Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

April 4
Last Trade: 1.14 0.02 1.79

SAN FRANCISCO, April 04, 2024 (GLOBE NEWSWIRE) -- Augmedix (Nasdaq: AUGX), a leader in ambient AI medical documentation and data solutions, today announced its go-to-market partnership with SADA, an Insight company, a leading cloud business and technology consultancy. The collaboration is focused on leveraging the companies’ combined technology expertise and expanding their reach to provide greater product and service value to health...Read more

Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

April 4
Last Trade: 49.84 -4.24 -7.84

Initiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center ROCHESTER, Minn. & MADISON, Wis. / Apr 04, 2024 / Business Wire / Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic...Read more

Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...